LOGIN  |  REGISTER
Amneal Pharmaceuticals

DocGo to Announce Third Quarter 2023 Results on Monday, November 6, 2023

October 23, 2023 | Last Trade: US$1.50 0.06 -3.85
  • Management to host conference call and webcast at 5:00 p.m. EDT on that day

NEW YORK / Oct 23, 2023 / Business Wire / DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider of technology-enabled mobile health services, today announced that the Company will release its financial results for the third quarter ended September 30, 2023 after the markets close on Monday, November 6, 2023. Management will also host a conference call to discuss these results at 5:00 p.m. EDT on that day.

Conference call and webcast details:

Monday, November 6, 2023
5:00 p.m. EDT
1-877-407-0784 (U.S.)
1-201-689-8560 (international)
Conference ID: 13741345
To access the Call me™ feature, which avoids the need to wait for an operator, click here.

A webcast of the conference call can be accessed under Events on the Investors section of the Company’s website at https://ir.docgo.com/.

About DocGo

DocGo is leading the proactive health care revolution with an innovative care delivery platform that includes mobile health services, remote patient monitoring and ambulance services. DocGo disrupts the traditional four-wall healthcare system by providing high quality, highly accessible care to patients where and when they need it. DocGo's proprietary technology and dedicated field staff of certified health professionals elevate the quality of patient care and drive business efficiencies for facilities, hospital networks, and health insurance providers. With mobile health, DocGo empowers the full promise and potential of telehealth by facilitating healthcare treatment, in tandem with a remote physician, in the comfort of a patient's home or workplace. Together with DocGo's integrated Ambulnz medical transport services, DocGo is bridging the gap between physical and virtual care. For more information, please visit www.docgo.com.

C4 Therapeutics

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page